Americas GERD & NERD Treatment Market 2018; Vital Players like Cempra, Eisai, Jeil pharmaceutical, Takeda Pharmaceutical, etc. by 2023

Americas GERD & NERD Treatment Market Report include on MarketReseacrhFuture.com with exhaustive Study. The report aims to provide an overview of Americas GERD & NERD Treatment Market Report. The report provides key statistics on the market status. Global Forecast till 2023.

Americas GERD & NERD Treatment Market - Dynamics

Heartburn is the burning sensation in the chest behind the breastbone that we feel when stomach acid refluxes back into the esophagus (food tube). Increasing prevalence of gastric diseases has increased the investment in GERD medication for research and development. This is expected to further drive the demand for gastroenteric drugs. The Americas GERD & NERD treatment market is expected to grow at the CAGR of 4.02% during the forecast period 2017-2023.

Get Exclusive Sample Copy of GERD & NERD Treatment Market `spread across 88 Premium Pages, 10+ and Supported with Full TOC, is Available @ https://www.marketresearchfuture.com/sample_request/5554

Over the last two hundred years, acid reflux has been a common lifestyle problem and also experienced a few setbacks in the U.S. Though, the ultimate goal of the gastroesophageal reflux treatment has always remained the same, which is to suppress the symptoms of the GERD patient. GERD affects up to 40% of the U.S. population in their lifetime and is a part of an increasingly significant public health burden. When GERD is not properly managed, it can lead to Barrett's esophagus. The lifetime risk of progression from GERD to Barrett's esophagus is 26.5%. Early diagnosis and treatment of Barrett's esophagus are crucial because it is the primary risk factor for esophageal cancer. The incidence of acid reflux disorder, also known as heartburn, is rapidly increasing worldwide. Various studies state that almost every person experiences acid reflux once in a lifetime. GERD is one of the commonly observed recurrent gastrointestinal disorders worldwide. The prevalence of acid reflux and related symptoms has increased across the globe by nearly 50% over the last decade. This disorder not only has major effects on the health and quality of patient lives but also extends to the healthcare system and economy.

major driving factors for growth of the market are increasing cases of smoking, rising cases of reflux disorder during pregnancy, changing lifestyle, and irregular dietary habits. Moreover, increasing incidence of acid reflux disorder (heartburn), growing geriatric population are likely to fuel the market growth during the forecast period.

Top Players:

Some of the major players in this market are: AstraZeneca Plc (U.K), Boston Scientific Corporation (U.S.), Cempra Inc. (U.S.), Eisai Co., Ltd. (Japan), EndoGastric Solutions Inc. (U.S.), EndoStim Inc. (U.S.), GlaxoSmithKline Plc (U.K), Ironwood Pharmaceuticals, Inc. (U.S.), Jeil pharmaceutical Co. Ltd. (South Korea), Johnson & Johnson (U.S.), Mederi Therapeutics Inc. (U.S.), Medigus Ltd., etc.

Market Segmentation:

Americas GERD & NERD treatment market is segmented on the basis of drug class, dosage form, and end user. On the basis of drug class, the market is segmented into antacids (acid neutralizers), proton pump inhibitors, H2 receptor blocker, prokinetic agents, antidepressants, calcium channel blockers, and others. Proton pump inhibitors are further segmented into esomeprazole, omeprazole, pantoprazole, lansoprazole, dexlansoprazole, rabeprazole, and others. H2 receptor blocker is further segmented into ranitidine, famotidine, cimetidine, nizatidine, and others. Prokinetic agents are further segmented into domperidone, metoclopramide, itopride, prucalopride, cisapride, benzamide, mosapride, erythromycin, and others. Based on the dosage form, it is segmented into solid and liquid. On the basis of the end user, it is segmented into hospitals & clinics, research centers, and others.

Avail Stunning Discount @ https://www.marketresearchfuture.com/check-discount/5554

Comprehensive Regional Analysis:

Considering the Americas GERD & NERD treatment market, there are two main regions: North America, and South America. North America consists of U.S. and Canada. The U.S. holds the largest market share due to the increasing burden of diseases, the share for gastric diseases is also increasing. The prevalence of acid reflux and related symptoms are increased across the globe by nearly 50% over the last decade.

Moreover, among all the geographical regions, North America has the highest GERD (gastroesophageal reflux disease) prevalence of 18.1%-27.8%. In North America, the U.S. has the highest prevalence of 26.2%.

According to the University of Michigan, more than 60 million American adults suffer from heartburn at least once a month and over 25 million experience heartburn daily. About 42% of the U.S. population experience heartburn at some point.

Major TOC of GERD & NERD Treatment Market Research Report - Americas Forecast till 2023:

1 Report Prologue

2 Market Introduction

3 Research Methodology

4 Market Dynamics

5 Market Factor Analysis

6 Americas GERD & NERD Treatment Market, by Drug class

7 Americas GERD & NERD Treatment Market, by Dosage Form

8 Americas GERD & NERD Treatment Market, by End User

9 Americas GERD & NERD Treatment Market, by Region

10 Competitive Landscape

11 Company Profiles

12 Appendix

13 MRFR Conclusion

Ask any Queries to Experts about Niche Segments, Requires Regional Data and Top Players @ https://www.marketresearchfuture.com/enquiry/5554

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com

This release was published on openPR.